Literature DB >> 35529287

Prolonged Large Seroma Formation after Breast-Conserving Therapy.

Shuhei Suzuki1, Shoji Oura1, Shinichiro Makimoto1.   

Abstract

A 78-year-old obese woman with breast cancer underwent breast-conserving surgery and axillary lymph node dissection. Due to the prior exposure to long-term taxan chemotherapy for her recurrent gastric cancer, the patient did not undergo adjuvant chemotherapy and began to receive radiotherapy to both the conserved breast and supraclavicular region on the 39th day after operation. Two aspiration therapies were done to the enlarging seroma only at the initial phase of the radiotherapy. No further aspiration therapies were done to the seroma during and after radiotherapy for more than 3 months despite the undoubtable seroma formation. High degree of tension due to large seroma formation, extended from the axilla to deep into the breast parenchyma, made the patient request us to heal the long-lasting seroma. Five aspiration therapies and one simultaneous minocycline intrathecal injection therapy did not bring about wound healing. To heal the persistent seroma, capsulectomy was done to the encapsulated lesion 7 months after the operation. Resected capsule was 110 × 45 mm in size and had smooth inner surface. Pathological study showed the seroma capsule mainly consisting of fibrous tissue with some inflammatory changes. Postoperative course was uneventful, and wound healing was promptly obtained after capsulectomy. Breast surgeons and radiation oncologists should note this type of unfavorable radiation-induced adverse event after breast-conserving therapy.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Capsulectomy; Long-lasting seroma; Radiotherapy

Year:  2022        PMID: 35529287      PMCID: PMC9035919          DOI: 10.1159/000522557

Source DB:  PubMed          Journal:  Case Rep Oncol        ISSN: 1662-6575


Introduction

Breast-conserving therapy has greatly contributed to the well-being of breast cancer patients. Breast-conserving therapy consists of partial resection of the affected breast and postoperative adjuvant radiotherapy to the conserved breast. It is well known that postoperative radiotherapy can reduce in-breast recurrence to a third compared to that of partial mastectomy alone. Therefore, breast cancer patients except for older patients with positive estrogen receptor and negative surgical margins should receive radiotherapy to the conserved breast of its beginning within 20 weeks [1] after breast-conserving surgery. Adjuvant radiotherapy to the conserved breast can contribute to the local control on the one hand but cause long-term and short-term toxicities on the other hand. The former includes cardiotoxicity, lung injury, and second malignancies. The latter includes arm edema, skin fibrosis, pneumonitis, and inhibition of wound healing. Breast-conserving surgery, i.e., main treatment for operable early breast cancer, also can cause seroma formation [2] and breast infection [3]. The former is much often observed compared to the latter in daily clinical practice and generally needs at least one or two aspiration therapies to the enlarging seroma. This complication is more often clinically observed in obese patients than in average or lean patients [4]. We herein report a rare case of prolonged large seroma formation after breast-conserving therapy.

Case Report

A 78-year-old obese, i.e., body mass index of 28.8, woman with a luminal type breast cancer in her left upper and outer quadrant of the breast underwent breast-conserving surgery and axillary dissection in February 2020. The patient had developed liver hilus node recurrence from gastric cancer approximately 8 years before and had been heavily treated with the second-line paclitaxel chemotherapy for more than 5 years in addition to the short-term first-line cisplatin-containing chemotherapy. She fortunately got a presumed cure of the gastric cancer recurrence but suffered from severe and irreversible peripheral neuropathy with the paclitaxel chemotherapy. The patient, therefore, began to receive adjuvant endocrine therapy using aromatase inhibitor without chemotherapy despite the confirmation of massive lymph node metastases after breast cancer surgery. The patient also began to receive radiotherapy to both the conserved breast and supraclavicular region on the 39th postoperative day. The patient received aspiration therapy for the enlarging seroma two times at the beginning of radiotherapy but did not receive aspiration therapy thereafter as directed by the radiation oncologist even though undoubtable seroma formation was observed. The patient unfortunately began to develop etiology-unknown diarrhea just after the completion of radiotherapy and was hospitalized to alleviate the abdominal symptom for a month. After discharge from the hospital with some symptom relief, i.e., at more than 3 months from the completion of radiotherapy, strong local tension due to large seroma formation made the patient request us to heal the long-lasting seroma (Fig. 1). Ultrasound showed massive and persistent fluid retention and presumed capsule formation just around the seroma. Computed tomography showed a large seroma extending from the axilla to deep into the conserved breast parenchyma with presumed capsule formation (Fig. 2). Five aspiration therapies did not lead to wound healing. Simultaneous minocycline, i.e., 100 mg diluted in 20 mL saline, intrathecal injection once into the seroma cavity did not cause tissue adhesion either. To heal the persistent seroma, capsulectomy under general anesthesia was planned 7 months after the operation. In the operation, almost all the capsule except for the part of presumed attachment to the axillary vein was surgically resected. The resected capsule was 110 × 45 mm in size and had smooth inner surface (Fig. 3a, b). Pathological study showed a seroma capsule consisting of fibrous connective tissue with hyalinization, no epithelial cells, and mild precipitation of fibrin on the surface of pseudocystic wall. In the superficial layer of the pseudocystic wall, aggregation of foamy histiocytes, infiltration of lymphocytes, and growth of capillary blood vessels were observed (Fig. 3c, d). The patient recovered uneventfully, was discharged on the 8th postoperative day, and thereafter showed prompt wound healing.
Fig. 1

Skin protrusion due to large seroma formation. Marked skin protrusion (arrows) was observed in the upper and outer quadrant of the left breast.

Fig. 2

CT around the left axilla. a Coronal view of the CT showed an oval iso-intensity lesion encompassed by presumed thick fibrous capsule (arrows). b Axial view of the CT showed an encapsulated presumed seroma located from the axilla to deep into the breast parenchyma (arrows). CT, computed tomography.

Fig. 3

Pathological findings of the resected capsule. a The capsule was almost completely resected and was 110 × 45 mm in size. b The thickness of the resected capsule was relatively uniform, and its luminal surface was smooth. c Low magnified view of the resected capsule showed ring shape fibrous tissue, the overlying skin (arrow), and subcutaneous fat tissue with partial fat necrosis (asterisks). d Magnified view of the specimen showed massive collagen fiber with hyalinization and aggregation of foamy histiocytes (arrow).

Discussion

After applying primary breast-conserving surgery for breast cancer patients with massive lymph node metastases, adjuvant chemotherapy generally precedes both radiotherapy and endocrine therapy [5]. More than ten lymph node metastases in this case, therefore, should have made the patient receive intensive adjuvant chemotherapy, e.g., dose-dense chemotherapy [6]. This patient, however, had already received more than 5 years' weekly paclitaxel chemotherapy, resulting in irreversible peripheral neuropathy and extremely rare long-lasting clinical complete response of the lymph node recurrence from gastric cancer in the liver hilum. This patient, therefore, seemed unlikely to benefit from adjuvant taxan chemotherapy with the intent to reduce the recurrence rate of breast cancer. Anthracycline-containing chemotherapy was also judged to have little or, even if present, nominal benefit to the patient as a postoperative adjuvant chemotherapy when considering the patient's age of 78 years old [7]. The patient, therefore, started to receive adjuvant endocrine therapy without chemotherapy. Fibrous capsule is generally formed just around the silicone implant, and capsular contracture often aggravates the cosmetic outcome of the patients after silicone-based breast reconstruction [8, 9]. In addition, after capsule formation, simple silicone removal due to either infection or silicon damage generally leads to persistent seroma formation in the capsule and never results in wound healing unless at least major part of the capsule is removed. It, therefore, is very important to avoid capsule formation after breast cancer surgeries. Possible measures to prevent seroma formation include postoperative full lymph drainage, appropriate aspiration of enlarging seroma followed by compression of the seroma cavity with some kind of girdle, and intrathecal injection of some chemical irritants such as minocycline and picibanil into the seroma cavity. Local control and survival rates are lower if postoperative irradiation begins later than 20 weeks after surgery [1]. In this case, the patient began to receive adjuvant radiotherapy about 6 weeks after surgery. The timing of starting radiotherapy itself seemed to be common and reasonable, but we lacked the discreetness, probably due to the massive lymph node involvement, to start radiotherapy after making a proper judgment about wound healing. In addition, radiation oncologist's concern that aspiration therapy to the enlarging seroma could affect the efficacy and side effects of radiotherapy also had a major impact on the persistent large seroma formation in this case. We had reported a case of massive seroma formation after breast cancer surgery successfully treated with intrathecal minocycline injection [10]. In this case, we also did the intrathecal minocycline injection into the seroma cavity once, only leading to minor histological findings of mild precipitation of fibrin on the surface of pseudocystic wall and no adhesion of the pseudocystic walls. To the best of our knowledge, this is the first case of prolonged large seroma formation extending from the axilla to deep into the breast parenchyma encompassed by fibrous capsule without silicone-based breast reconstruction. It is well known that some kind of solid foreign body is generally separated by fibrous capsule, resulting in spherical transformation in order to minimize the contact area between the human body and the foreign body when the foreign body being deformable. To date, there should have been quite a few cases in which radiation therapy was started without complete healing of the wound in clinical practice. Why this persistent large seroma occurred in this patient remains unclear. But breast surgeons and radiation oncologists should note this minor but clinically important adverse event after breast-conserving therapy. In conclusion, breast surgeons should pay much attention to the postoperative persistent seroma formation to avoid the aggravation of quality of life of the breast cancer patients.

Statement of Ethics

The study was approved by the Kishiwada Tokushukai Hospital Ethics Committee (IRB #Case 20-04). Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No funding was received for this research.

Author Contributions

Suzuki S. contributed to the design of the report. Oura S. drafted the manuscript. Makimoto S. revised the manuscript. All authors have read and approved the final version of the manuscript.

Data Availability Statement

All data generated during this study are included in this article. Further inquiries can be directed to the corresponding author.
  10 in total

Review 1.  Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.

Authors:  Igor Lemos Duarte; João Paulo da Silveira Nogueira Lima; Carmen Silvia Passos Lima; André Deeke Sasse
Journal:  Breast       Date:  2012-03-15       Impact factor: 4.380

Review 2.  Incidence of clinically significant seroma after breast and axillary surgery.

Authors:  Sarah Y Boostrom; Alyssa D Throckmorton; Judy C Boughey; Andrea C Holifield; Shaheen Zakaria; Tanya L Hoskin; Amy C Degnim
Journal:  J Am Coll Surg       Date:  2008-10-02       Impact factor: 6.113

Review 3.  Capsular contractures: a systematic review.

Authors:  Antonino Araco; Riccardo Caruso; Francesco Araco; John Overton; Gianpiero Gravante
Journal:  Plast Reconstr Surg       Date:  2009-12       Impact factor: 4.730

Review 4.  Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy.

Authors:  Alessandra Balduzzi; Maria Cristina Leonardi; Anna Cardillo; Roberto Orecchia; Silvia Dellapasqua; Monica Iorfida; Aron Goldhirsch; Marco Colleoni
Journal:  Cancer Treat Rev       Date:  2010-03-20       Impact factor: 12.111

5.  Risk factor analysis for breast cellulitis complicating breast conservation therapy.

Authors:  V H Brewer; K A Hahn; B W Rohrbach; J L Bell; L M Baddour
Journal:  Clin Infect Dis       Date:  2000-09-21       Impact factor: 9.079

Review 6.  Capsular contracture with breast implants in the cosmetic patient: saline versus silicone--a systematic review of the literature.

Authors:  Timothy A Schaub; Jamil Ahmad; Rod J Rohrich
Journal:  Plast Reconstr Surg       Date:  2010-12       Impact factor: 4.730

Review 7.  Seroma following breast cancer surgery.

Authors:  C J Pogson; A Adwani; S R Ebbs
Journal:  Eur J Surg Oncol       Date:  2003-11       Impact factor: 4.424

8.  Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy.

Authors:  Ivo A Olivotto; Mary L Lesperance; Pauline T Truong; Alan Nichol; Tanya Berrang; Scott Tyldesley; François Germain; Caroline Speers; Elaine Wai; Caroline Holloway; Winkle Kwan; Hagen Kennecke
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

Review 9.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

Authors:  M Clarke; A S Coates; S C Darby; C Davies; R D Gelber; J Godwin; A Goldhirsch; R Gray; R Peto; K I Pritchard; W C Wood
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.